Clinical trials: Normal Lungs
Liver Cancer, Lung Cancer
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion…
- Conditions
- Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
- Trial name
- NCT04842812
- Testing
- TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Acute Leukemia, Multiple Myeloma
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk.
- Conditions
- Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma
- Trial name
- IT-TCP POS (NCT07403630)
- Testing
- Functional tests, Multi-omics analyses, Cytogenetics/ FISH
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Breast Cancer, Lung Cancer
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT05137067
- Testing
- Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Optimal Health Research
Breast Cancer, Breast Neoplasm
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
The accuracy of breast examinations and ultrasonography performed clinically to detect breast mass varies greatly depending on the physician\'s skill level, and the accuracy of breast examinations by non-experts is…
- Conditions
- Breast Cancer, Breast Neoplasm, Artificial Intelligence, Ultrasonography
- Trial name
- NCT06255808
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer
- Trial name
- NCT00101348
- Testing
- erlotinib hydrochloride, cetuximab, bevacizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
NUT Midline Carcinoma, Triple Negative Breast Cancer
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
Open-label, phase I, non-randomized, multicentric study of single-agent birabresib (MK-8628) (formerly known as OTX015) administered according to two distinct regimens to participants with selected advanced tumors.
- Conditions
- NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer
- Trial name
- NCT02259114
- Testing
- Birabresib
- Volunteers
- 47 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Neoplasms, Neoplasms, Glandular and Epithelial
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02897778
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Soft Tissue Sarcoma, Pulmonary Metastasis
Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
This study is a multi-centre, open-label, single-arm, 3+3 Phase 1b/ and Phase II. Phase 1b is aimed to determine the maximum-tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) based on safety reporting.
- Trial name
- ANNA-SARC (NCT05518526)
- Testing
- Liposomal Annamycin (L-Annamycin)
- Where
- Poland
- Volunteers
- 64 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Breast Cancer, Lung Cancer
Implementation, Effectiveness and Impact of a Value Based Intervention for Patients with Breast or Lung Cancer
VOICE project aims to guide health services in their reorganization towards the provision of the highest value care for the patient at the best cost. VOICE is targeted to patients with breast and lung cancer.
- Trial name
- VOICE (NCT04960735)
- Testing
- VOICE intervention
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 1,007 people
- Sponsor
- Biosistemak Institute for Health Systems Research
Male Breast Cancer, Recurrent Breast Cancer
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer
- Trial name
- NCT00028535
- Testing
- trastuzumab, paclitaxel, recombinant interleukin-12
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Interstitial Lung Disease, Scleroderma
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Inflammatory Myositis, Mixed Connective Tissue Disease
- Trial name
- RECITAL (NCT01862926)
- Testing
- Rituximab, Cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Thoracic Sarcomas, Thorasic Cancers
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Background: During recent years, cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X genes), have emerged as attractive targets for cancer immunotherapy.
- Conditions
- Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura, Sarcoma
- Trial name
- NCT02054104
- Testing
- H1299 cell lysates, Cyclophosphamide, Celecoxib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Interstitial Lung Disease
Pulmonary Rehabilitation in Interstitial Lung Disease
Interstitial lung disease (ILD) is a highly disabling group of conditions including idiopathic pulmonary fibrosis (IPF), acute and chronic interstitial pneumonias, connective tissue diseases and sarcoidosis.
- Trial name
- NCT00168285
- Testing
- Pulmonary Rehabilitation
- Where
- 2 sites in Australia
- Volunteers
- 56 people
- Sponsor
- The Alfred
Enterobacteriaceae Infections, Bacteremia
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
To assess the molecular epidemiology, clinical impact, treatment outcome and risk factors for infections caused by Enterobacteriaceae producing ESBLs in Italy in a large multicenter observational survey. SPECIFIC OBJECTIVES 1.
- Conditions
- Enterobacteriaceae Infections, Bacteremia, Pneumonia, Skin Diseases
- Trial name
- NCT00404625
- Testing
- Risk factors for infections due to ESBL+ Enterobacteriaceae, Risk factors for inadequate initial antimicrobial therapy, Overall and 30-day mortality in bad first antibiotic therapy
- Where
- 6 sites in Italy
- Volunteers
- 813 people
- Sponsor
- University of Siena
Advanced Cancers
Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer
The goal of this clinical research study is to learn if Lipitor (atorvastatin) or fish oil supplements can help to control side effects of the heart that are commonly seen after lung surgery (such as irregular heartbeat).
- Trial name
- NCT01259284
- Testing
- Atorvastatin, Fish Oil Supplement
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Carcinoma, Head and Neck Cancer
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer
This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer.
- Conditions
- Breast Carcinoma, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT05787834
- Testing
- Best Practice, Medical Device Usage and Evaluation, Respiratory Muscle Training
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Lung Cancer
Cardiotoxicity of Radiation Therapy (CTRT)
The overall objective of this proposal is to determine the utility of sensitive imaging and biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation doses to the heart.
- Conditions
- Breast Cancer, Lung Cancer, Mediastinal Lymphomas
- Trial name
- NCT02769299
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer, Non Small Cell Lung Cancer (NSCLC)
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effect of food on the pharmacokinetics (PK) of the experimental drug, entinostat, in women with breast cancer and men and women with non-small cell lung cancer.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
- Trial name
- ENCORE110 (NCT01594398)
- Testing
- entinostat, Erlotinib, Exemestane
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Syndax Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.